DRKS00023862已完成不适用
Impact of CFTR-modulation with elexacaftor/tezacaftor/ivacaftor on the exercise capacity, intestinal and respiratory microbiome, microbial and inflammatory metabolites in cystic fibrosis - IMMProveCFInflammation, Microbiome, Metabolome and physical Performance in Cystic Fibrosis
Zentrum für Kinder- und Jugendmedizin der Universitätsmedizin Mainz0 个研究点目标入组 84 人开始时间: 2021年6月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 6 Years 至 100 Years（—）
- 性别
- All
入选标准
- •Age 6 and older
- •- Confirmed diagnosis and mutation
- •- Planned to start medication with elexacaftor/tezacaftor/ivacaftor
- •- Written informed consent (from parent or legal guardian if underaged)
- •Or sex- and aged matched healthy control
排除标准
- •- Comorbidity which exclude therapy with elexacaftor/tezacaftor/ivacaftor (e.g liver or renal insufficiency)
- •- Respiratory infection at the start of treatment
- •- Acute therapy changes 21 days before starting therapy with elexacaftor/tezacaftor/ivacaftor
- •- Antibiotic treatment up to 3 weeks prior to study start
研究者
相似试验
进行中（未招募）
1 期
Study of the effects of combined treatment with the CFTR corrector ivacaftor and IV antibiotics on infection in CF.Cystic fibrosisEUCTR2016-001785-29-IESt. Vincent's University Hospital
已完成
不适用
Effect of One Year Elexacaftor-tezacaftor-ivacaftor TreatmentCystic FibrosisNCT06331000University Hospital, Strasbourg, France184
尚未招募
不适用
Effectiveness of CFTR Modulators According to Co-therapyCystic FibrosisNCT05663255Hospices Civils de Lyon1,990
招募中
早期 1 期
Personalized Theratyping TrialCystic FibrosisNCT03587961George Solomon20
已完成
4 期
OrkambiKIDS: Impact of CFTR-modulation with Lumacftor/Ivacaftor on the intestinal and respiratory microbiome and microbial metabolites in children aged 2 to 12 with cystic fibrosisE84.0Cystic fibrosis with pulmonary manifestationsDRKS00022267Children's Hospital, University medical center Mainz8